Atypical Teratoid Rhabdoid Tumor – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Atypical Teratoid Rhabdoid Tumor – Drugs In Development, 2024 report and make more profitable business decisions.
Atypical teratoid rhabdoid tumor (ATRT) is a rare and fast-growing cancerous tumor of the brain and spinal cord. About half of these tumors begin in the cerebellum or brain stem. ATRT often appears to result from changes in a gene that normally makes proteins to stop tumor growth. In ATRT, this gene does not function properly, the protein is not made and tumor growth is uncontrolled. More than 90% of cases of ATRT are related to this gene defect. While this defect commonly occurs only within the cancer, this gene defect may be inherited.
The Atypical Teratoid Rhabdoid Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Atypical Teratoid Rhabdoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atypical Teratoid Rhabdoid Tumor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Atypical Teratoid Rhabdoid Tumor | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 17 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Atypical Teratoid Rhabdoid Tumor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Atypical Teratoid Rhabdoid Tumor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Atypical Teratoid Rhabdoid Tumor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Chimerix IncF. Hoffmann-La Roche Ltd
Ipsen SA
Istari Oncology Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Nationwide Children's Hospital
NightHawk Biosciences Inc
Novartis AG
OrphAI Therapeutics Inc
Puma Biotechnology Inc
Starlight Therapeutics Inc
Titan Pharmaceuticals Inc
Treovir LLC
Vyriad Inc
Vyro Bio Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pharmaceuticals reports